Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Next Previous
Trial Profile

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Losartan
  • Indications Diabetic nephropathies; Hypertension
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms ASPIRE-HIGHER; AVOID
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 21 May 2021 This trial has been discontinued in Ireland, as per European Clinical Trials Database record.
    • 24 Sep 2010 Results from the sub-study that investigated the effect of treatment on renal function presented at the 46th Annual Meeting of the European Association for the Study of Diabetes
    • 24 Oct 2009 Results of an economic analysis were presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top